Servier Pharmaceuticals said the US FDA approved its treatment for a type of brain tumour, becoming the first drug to gain approval in the US for the disease. The drug, known as voranigo, is used to treat a form of brain cancer, called IDH-mutated grade 2 glioma, in patients who have undergone surgery.